Pre-mixes of GLP-1 and basal insulin

Details Pre-mixes of GLP-1 and basal insulin Pre-mixes of GLP-1 and basal insulin

2007-07-03

2007-07-03

Tsang, Cecilia J. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S003100

Reexamination Certificate

active

10486333

ABSTRACT:
The present invention encompasses pre-mixed formulations comprising a GLP-1 polypeptide and a basal insulin.

REFERENCES:
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5461031 (1995-10-01), De Felippis
patent: 5512549 (1996-04-01), Chen et al.
patent: 5514646 (1996-05-01), Chance et al.
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5547929 (1996-08-01), Anderson, Jr. et al.
patent: 5650486 (1997-07-01), De Felippis
patent: 5656722 (1997-08-01), Dorschug
patent: 5705483 (1998-01-01), Galloway et al.
patent: 5747642 (1998-05-01), De Felippis
patent: 5840680 (1998-11-01), Balschmidt
patent: 5977071 (1999-11-01), Galloway et al.
patent: 6011007 (2000-01-01), Havelund et al.
patent: 6133235 (2000-10-01), Galloway et al.
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: 6221633 (2001-04-01), Ertl et al.
patent: 6221837 (2001-04-01), Ertl et al.
patent: 6268335 (2001-07-01), Brader
patent: 6268343 (2001-07-01), Knudsen et al.
patent: 6277877 (2001-08-01), Hoover et al.
patent: 6875741 (2005-04-01), Pillutla et al.
patent: 2001/0047084 (2001-11-01), Knudsen et al.
patent: 2003/0224983 (2003-12-01), Nielsen
patent: 2003/0236190 (2003-12-01), Pillutla et al.
patent: WO 95/07931 (1995-03-01), None
patent: WO 95/31214 (1995-11-01), None
patent: WO 99/07404 (1999-02-01), None
patent: WO 99/25727 (1999-05-01), None
patent: WO 99/25728 (1999-05-01), None
patent: WO 99/32116 (1999-07-01), None
patent: WO 99/43708 (1999-09-01), None
patent: WO 00/37098 (2000-06-01), None
patent: WO 00/66629 (2000-11-01), None
patent: WO 03/053339 (2003-07-01), None
Adelhorst, et al., “Structure-Activity Studies of Glucagon-Like Peptide-1.” 1994, J. Biological Chemistry vol. 269: 6275-6278.
Brange, “Galenics of Insulin: The Physico-chemical and Pharmaceutical Aspects of Insulin and Insulin Preparation.” 1987.
Markussen, et al., “Soluble, Prolonged-acting Insulin Derivatives.III. Degree of Protraction, Crystallizability and Chemical Stability of Insulins Substituted in Positions A21, B13, B23, B27 and B30.” Protein Eng. 1988, vol. 2: p. 157-166.
Markussen, et al., “Soluble, Fatty Acid Acylated Insulins Bind to Albumin and Show Protracted Action in Pigs.” Diabetologia, 1996, vol. 39, pp. 281-288.
Myers, et al., “Acylation of Human Insulin With Palmitic Acid Extends the Time Action of Human Insulin in Diabetic Dogs.” Diabetes, 1997, vol. 46, pp. 637-642.
Vella, et al., “Effect of Glucagon-Like Peptide 1 (7-36) Amide on Glucose Effectiveness and Insulin Action in People With Type 2 Diabetes.” Diabetes, Apr. 2000, vol. 49, pp. 611-617.
Zander, et al., “Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes.” Apr. 2001, vol. 24, No. 4, pp. 720-725.
U.S. Appl. No. 09/538,038, Mar. 29, 2000, ABD'd.
U.S. Appl. No. 09/146,127, Sep. 2, 1998, ABD'd.

Affiliated with

Also associated with

Rating

Pre-mixes of GLP-1 and basal insulin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pre-mixes of GLP-1 and basal insulin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pre-mixes of GLP-1 and basal insulin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3724270